구연산 카페인 시장 예측(-2030년) : 유형별, 용도별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Caffeine Citrate Market is growing at a CAGR of 3.2% during the forecast period. A drug known as caffeine citrate mixes the stimulant caffeine, which acts on the central nervous system, with the weak organic citric acid. Premature infants who suffer from apnea of prematurity frequently have breathing pauses. Apnea of prematurity (AOP) is the condition for which it is primarily used in the field of neonatal care, specifically in neonatal intensive care units (NICUs).

According to scientists at the FDA, caffeine can be part of a healthy diet for most people, but too much caffeine may pose a danger to your health. Depending on factors such as body weight, medications you may take, and individual sensitivity, "too much" can vary from person to person.

Market Dynamics:

Driver:

Wide usage for treatment of Apnea of Prematurity (AOP)

One major factor propelling the market is the widespread use of caffeine citrate in the management of apnea of prematurity (AOP). Breathing irregularities and breathing pauses are characteristic features of AOP, a common condition in premature infants. The respiratory center of the baby is stimulated by the stimulant qualities of caffeine citrate, which lessens the frequency and intensity of apnea episodes. Additionally, caffeine citrate is in high demand in neonatal care due to its effectiveness, safety, and ease of administration, which also highlights the vital role it plays in promoting the health and survival rates of premature infants, which is promoting market growth.

Restraint:

Price fluctuations

Citric acid and caffeine are among the raw materials used in the market. Production costs may rise as a result of these inputs' erratic prices, which are influenced by worldwide supply, crop yields, and general economic conditions. Competitive pricing and profitability may suffer if manufacturers are unable to keep up steady prices for their products containing caffeine citrate. Additionally, if the price of caffeine citrate is unstable, consumers and healthcare professionals might be reluctant to use it, which could restrict market stability and growth.

Opportunity:

Increasing NICU admissions

Market opportunities for caffeine citrate are greatly increased by the growing number of admissions to neonatal intensive care units (NICUs). Newborns in critical condition, including preterm infants at risk for Apnea of Prematurity (AOP), are admitted to NICUs. Caffeine citrate, a common treatment for AOP, is in greater demand as NICU admissions rise as a result of advancements in healthcare, higher birth complications, and improved neonatal survival rates. An additional factor supporting the market's potential for growth is the increased patient pool that this spike in NICU admissions generates for caffeine citrate. This presents a significant growth avenue for producers and healthcare providers.

Threat:

Regulatory restrictions

Government rules are essential for managing the manufacture, labeling, and distribution of pharmaceutical items such as caffeine citrate. Modifications to these laws, which cover things like safety requirements and labeling specifications, may make it harder for manufacturers to comply with the law and raise their expenses. Furthermore, products may need to be reformulated or taken off the market due to strict regulations or the discovery of new safety concerns. Market expansion may be hampered by such uncertainties and compliance requirements.

COVID-19 Impact:

The COVID-19 pandemic has exerted a mixed impact on the caffeine citrate market. The heightened focus on healthcare and the surge in hospital admissions initially bolstered demand for neonatal care, but disruptions in global supply chains and shifts in healthcare priorities led to some challenges. Lockdowns and strained healthcare resources affected production and distribution, causing sporadic shortages. However, the increased emphasis on neonatal health and the potential for ongoing research into caffeine citrate's applications post-COVID could pave the way for renewed growth and innovation in the market.

The healthcare segment is expected to be the largest during the forecast period

During the forecast period, the healthcare segment is anticipated to secure the largest share in the caffeine citrate market. This projection is attributed to the compound's fundamental role in neonatal and pediatric care, particularly for treating Apnea of Prematurity (AOP) in premature infants. As neonatal care standards and NICU admissions continue to rise, caffeine citrate remains a vital pharmaceutical solution, contributing to the segment's dominance. Furthermore, with its crucial role in improving the survival and well-being of premature infants, the healthcare sector is expected to maintain its prominence in driving the caffeine citrate market.

The injection segment is expected to have the highest CAGR during the forecast period

The injection segment is predicted to register a significant growth rate in the caffeine citrate market due to its critical role in neonatal care. Caffeine citrate injections are primarily used in the treatment of apnea of prematurity (AOP) in premature infants, providing a fast and precise means of delivering the medication. As neonatal care and NICU admissions continue to rise, the demand for caffeine citrate injections remains strong. The injectable form is essential for the initial treatment of AOP, making it a crucial component of neonatal healthcare. With the increasing focus on improving premature infant health, the injection segment is poised to play a pivotal role in propelling the market forward.

Region with largest share:

Caffeine citrate is widely used in neonatal care across the region to treat Apnea of Prematurity (AOP), a common condition in premature infants. Due to this factor, North America is anticipated to dominate the market throughout the forecast period. The presence of advanced healthcare infrastructure, rising NICU admissions, and a focus on improving neonatal care have contributed to the market's growth. Additionally, a strong emphasis on research and development in the pharmaceutical sector ensures continued product innovation and market expansion. Overall, the North American caffeine citrate market is well-positioned for sustained growth.

Region with highest CAGR:

The caffeine citrate market in the Asia Pacific region is expected to witness significant growth potential. The region's large population and a growing emphasis on improving neonatal care have resulted in increased NICU admissions, driving the demand for caffeine citrate to treat Apnea of Prematurity (AOP) in premature infants. Moreover, as healthcare infrastructure and access to neonatal care services continue to expand. Furthermore, the region's market is poised for expansion due to its demographic and healthcare developments.

Key players in the market

Some of the key players in Caffeine Citrate market include: Akorn, Amphastar Pharmaceuticals, Angel Labs, Fresenius Kabi, Mylan N.V., Novartis AG, Pasteur Laboratories Pvt Ltd, Perrigo Company plc, Pfizer Inc., Sagent Pharmaceuticals and Teva Pharmaceutical Industries Ltd.

Key Developments:

In October 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY™ (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely active ulcerative colitis (UC). The approved recommended dose for VELSIPITY is 2 mg.

In September 2023, Fresenius Kabi announced it has signed an agreement with Virginia Oncology Associates (VOA) under which VOA will purchase the Ivenix Infusion System to deliver medications for its patients. VOA specializes in treating people with cancer and blood disorders by providing access to innovative therapies and technologies.

In June 2023, Amphastar Pharmaceuticals, Inc. announced that it has completed the previously announced acquisition of BAQSIMI® from Eli Lilly and Company. Pursuant to the terms of the asset purchase agreement entered into by and between Amphastar and Lilly on April 21, 2023, Amphastar paid $500 million at the closing of the Acquisition and is required to pay an additional $125 million at the one-year anniversary of the closing of the Acquisition.

Types Covered:

• Injection
• Oral Solution
• Tablet

Applications Covered:

• Pharmaceuticals
• Healthcare
• Research & Development
• Other Applications

End Users Covered:

• Adults
• Pediatrics
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Application Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Caffeine Citrate Market, By Type

• 5.1 Introduction
• 5.2 Injection
• 5.3 Oral Solution
• 5.4 Tablet

6 Global Caffeine Citrate Market, By Application

• 6.1 Introduction
• 6.2 Pharmaceuticals
• 6.3 Healthcare
• 6.4 Research & Development
• 6.5 Other Applications

7 Global Caffeine Citrate Market, By End User

• 7.1 Introduction
• 7.2 Adults
• 7.3 Pediatrics
• 7.4 Other End Users

8 Global Caffeine Citrate Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Akorn
• 10.2 Amphastar Pharmaceuticals
• 10.3 Angel Labs
• 10.4 Fresenius Kabi
• 10.5 Mylan N.V.
• 10.6 Novartis AG
• 10.7 Pasteur Laboratories Pvt Ltd
• 10.8 Perrigo Company plc
• 10.9 Pfizer Inc.
• 10.10 Sagent Pharmaceuticals
• 10.11 Teva Pharmaceutical Industries Ltd.